Revenio Group Corporation
Research Revenio Group Corporation (REG1V) on Bullrun: valuation model: 42.6% undervalued, market cap EUR 391.63M, P/E 25.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerREG1V
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Valuation signal42.6% undervalued
- Market capEUR 391.63M
- P/E25.0
- Financial periodQ1 2026
- RevenueEUR 27.30M
- Net incomeEUR 2.50M
- Free cash flow-EUR 4.40M
- Gross margin68.5%
Valuation Snapshot
Bullrun's latest valuation model marks Revenio Group Corporation as 42.6% undervalued; latest market cap is EUR 391.63M; P/E is 25.0.
Peer valuation comparison
Latest P/E is 25.02x versus a Healthcare sector median of 24.46x (2.3% above).
Latest P/E is 25.02x versus a Finland median of 18.47x (35.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 109.70M | EUR 17.40M | n/a | 70.9% | n/a | EUR 26.24M | EUR 10.99M | EUR 114.70M |
| FY2024 | EUR 103.50M | EUR 18.60M | n/a | 70.5% | n/a | EUR 20.69M | EUR 12.78M | EUR 107.71M |
| FY2023 | EUR 96.80M | EUR 19.00M | n/a | 70.9% | n/a | EUR 21.54M | n/a | n/a |
| FY2022 | EUR 97.28M | EUR 21.65M | n/a | 72.1% | n/a | EUR 32.06M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 391.63M | 25.0 | 3.1% | 0.44 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.44 EUR.
About Revenio Group Corporation
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Revenio Group Corporation overvalued or undervalued?
Bullrun's valuation model currently marks Revenio Group Corporation as 42.6% undervalued.
What is Revenio Group Corporation's market cap?
Revenio Group Corporation's market capitalization is EUR 391.63M.
What is Revenio Group Corporation's P/E ratio?
Revenio Group Corporation's price-to-earnings (P/E) ratio is 25.0.
What does Revenio Group Corporation do?
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.